Jeena Sikho

Jeena Sikho reported strong financial results for FY26, with revenue from operations reaching ₹801 crores, marking a 71% year-on-year growth. EBITDA saw a substantial increase of 149% year-on-year to ₹349 crores, with the EBITDA margin expanding by 1,360 basis points to 44%. Net profit (PAT) also grew significantly by 177% year-on-year to ₹222 crores, achieving a 28% PAT margin. The company maintains a debt-free balance sheet, reflecting prudent financial management.

The company emphasizes its unique business model focused on preventive healthcare through Ayurveda, aiming to prevent people from falling ill rather than just treating them. This approach is supported by approximately 600 certified Ayurvedic and Naturopathy doctors and 750 wellness experts. Jeena Sikho positions itself as the first company in India dedicated to this preventive mission, leveraging thousands of years of Ayurvedic science as a first-choice, evidence-based system.

Jeena Sikho operates on a hub-and-spoke model with 58 hospitals and 59 daycare/clinical centers across 23 states and 100 cities. Currently, the company has 2,300 operational beds and plans to increase this to 3,000 beds within the next 3-4 months, with a long-term target of 7,000 to 10,000 beds in 3-5 years. The setup cost per bed is efficient at ₹3-4 lakh, and the payback period for small facilities is less than 6 months, with an average ROCE of 71% over 3 years.

The product vertical contributed ₹416 crores to revenue in FY26, accounting for 52% of the total, with gross margins exceeding 85%. The company is expanding its product portfolio into OTC pharmacy retail and international markets, particularly in the UAE. New products for female wellness (e.g., pregnancy-related) and child health are being launched, with trials completed and R&D efforts focused on evidence-based solutions.

Q4 FY26 results were affected by approximately ₹19-21 crores in one-time^📎, non-recurring^📎 expenses, including provisions for new labour codes, ESOPs, performance-linked bonuses, ECL, and leasehold adjustments. Additionally, geopolitical events like the Iran-America war caused panic, leading to a slight deferral of preventive patient visits and impacting Q4 patient volumes. Management clarified these were one-off^📎 or temporary impacts, not indicative of underlying business weakness.

The company aims for a 50-50 revenue mix between services and products in the long term. Strategically, Jeena Sikho reduced its government sales from ₹118 crores in FY25 to ₹36 crores in FY26 due to issues with credit getting stuck and delayed payments. This shift allowed the company to increase private hospital sales by over 2.5x, demonstrating agile management in optimizing revenue streams.

Jeena Sikho emphasizes its commitment to evidence-based Ayurveda, with approximately 550 papers written last year, of which about 400 have been accepted and over 180 published in peer-reviewed research. The company highlights its clinical trial-based product development and references seven Nobel Prize studies that inform its treatments. This focus on research underpins its credibility and long-term vision for global expansion.

The company launched the Swadeshi Health Card to strengthen patient loyalty through referral benefits, diagnostic discounts, and seamless service integration. This initiative, along with linking people with loyalty points, aims to convert satisfied patients into marketing channels. The goal is to build a community around preventive health, with a reported 26% repeat business for admitted patients and 34% for products.